The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...

Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...

Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00.

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Eli Lilly and (NYSE:LLY) with a Outperform ...

The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...